CENTURY THERAPEUTICS INC. - COMMON STOCK

0,7107

11-февраля-25 09:59:13

15 мин. задержка

Акции

-0,0112

-1,55%

Сегодняшний диапазон

0,6810 - 0,7208

ISIN

N/A

Источник

NASDAQ

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

21 янв 2025 07:00:19 Источник Nasdaq GlobeNewswire
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

26 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

05 ноя 2024 09:05:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

05 ноя 2024 09:00:01 Источник Nasdaq GlobeNewswire
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

04 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

26 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

03 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting

10 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

23 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

11 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

19 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

14 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

05 мар 2024 18:03:06 Источник Nasdaq GlobeNewswire
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

09 дек 2023 12:00:00 Источник Nasdaq GlobeNewswire
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

06 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

06 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.